Authorized purpose: MVision AI Segmentation automatically generates initial contours from CT images for radiotherapy planning; the contours are transferred for professional visualization, review, modification, and approval, and the labeled software is not intended for lesion or tumor detection or real-time adaptive planning.
Clinical role
Radiotherapy contouring, treatment planning, adaptation, or treatment-session support under professional review.
Images and patients
Radiotherapy Planning Imaging · Head and neck, brain, breast, lung and abdomen, male pelvis, and female pelvis structures
Key limitation
Keep in mind: Initial contours require professional visualization, review, modification, and approval; the labeled software is not intended for lesion or tumor detection or real-time adaptive planning.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: MVision AI Segmentation automatically generates initial contours from CT images for radiotherapy planning; the contours are transferred for professional visualization, review, modification, and approval, and the labeled software is not intended for lesion or tumor detection or real-time adaptive planning.
Which images or clinical context are in scope?Modality: Radiotherapy Planning Imaging Anatomy or clinical context: Head and neck, brain, breast, lung and abdomen, male pelvis, and female pelvis structures Input: Supported CT or MR images, structures, prescriptions, plans, registrations, and treatment-session data.
Who uses it?Intended users: Qualified radiation oncologists, medical physicists, dosimetrists, and radiation therapists.
What does the software produce?Output: Contours, treatment plans, adapted plans, dose or evaluation results, or session information requiring review and approval.
What is its most important limitation?Key limitation: Initial contours require professional visualization, review, modification, and approval; the labeled software is not intended for lesion or tumor detection or real-time adaptive planning.
Clinical takeaway. Clinical role: MVision AI Segmentation automatically generates initial contours from CT images for radiotherapy planning; the contours are transferred for professional visualization, review, modification, and approval, and the labeled software is not intended for lesion or tumor detection or real-time adaptive planning.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports software verification and validation, cybersecurity tests, and a performance evaluation of the machine learning segmentation algorithms using training and test sets (golden dataset) from multiple different sources, with performance validation by radiotherapy experts described as showing reduced upfront contouring effort and time. No quantitative results are given, and no animal studies or clinical tests were included in the submission. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
MVision AI Segmentation automatically generates initial contours from CT images for radiotherapy planning; the contours are transferred for professional visualization, review, modification, and approval, and the labeled software is not intended for lesion or tumor detection or real-time adaptive planning.
Initial contours require professional visualization, review, modification, and approval; the labeled software is not intended for lesion or tumor detection or real-time adaptive planning.
The exact FDA document reports software verification and validation, cybersecurity tests, and a performance evaluation of the machine learning segmentation algorithms using training and test sets (golden dataset) from multiple different sources, with performance validation by radiotherapy experts described as showing reduced upfront contouring effort and time. No quantitative results are given, and no animal studies or clinical tests were included in the submission. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Software verification and validation, performance evaluation for machine learning based algorithms, and implemented Cybersecurity control measures and tests establish that the subject medical device is safe," … "No animal studies or clinical tests have been included in this pre-market submission.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports software verification and validation, cybersecurity tests, and a performance evaluation of the machine learning segmentation algorithms using training and test sets (golden dataset) from multiple different sources, with performance validation by radiotherapy experts described as showing reduced upfront contouring effort and time. No quantitative results are given, and no animal studies or clinical tests were included in the submission. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Software verification and validation, performance evaluation for machine learning based algorithms, and implemented Cybersecurity control measures and tests establish that the subject medical device is safe," … "No animal studies or clinical tests have been included in this pre-market submission.". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not promoted as a product-wide endpoint for this device or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Specificity is not promoted as a product-wide endpoint for this device or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K212915 FDA evidence package for MVision AI Segmentation
DesignFDA 510(k) substantial-equivalence decision evidence and product verification described in the exact submission.
PopulationHead and neck, brain, breast, lung and abdomen, male pelvis, and female pelvis structures
Scopeexact submission
Tested versionMVision AI Segmentation configuration described in K212915
IndependenceSponsor or vendor study
K212915
Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K212915 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS radiation-oncology material. Evaluate net planning or delivery value within the radiotherapy service line.
No separate named-product payment identified in reviewed public material
Centers for Medicare & Medicaid Services · United States
This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported CT or MR images, structures, prescriptions, plans, registrations, and treatment-session data.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes DICOM TCP/IP for on-premises use and de-identified DICOM over HTTPS/TLS for cloud mode; verify the installed release and local controls.
Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, and archive behavior still require acceptance testing.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes on-premises and cloud deployment modes for the MVision AI Segmentation release; verify current hosting, contracts, security, availability, and site configuration locally.
Scope: Exact FDA submission. This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, and site configuration remain separate evidence.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Contours, treatment plans, adapted plans, dose or evaluation results, or session information requiring review and approval.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Contours, treatment plans, adapted plans, dose or evaluation results, or session information requiring review and approval.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes on-premises and cloud deployment modes for the MVision AI Segmentation release; verify current hosting, contracts, security, availability, and site configuration locally.
Exact FDA submission
Checked 2026-09-04
This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, and site configuration remain separate evidence.
The exact FDA package describes DICOM TCP/IP for on-premises use and de-identified DICOM over HTTPS/TLS for cloud mode; verify the installed release and local controls.
Exact FDA submission
Checked 2026-09-04
This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, and archive behavior still require acceptance testing.
Only qualified radiation oncologists, medical physicists, dosimetrists, and radiation therapists should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor K212915 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Initial contours require professional visualization, review, modification, and approval; the labeled software is not intended for lesion or tumor detection or real-time adaptive planning.
Exact FDA submission
Checked 2026-09-04
Monitoring guidance is buyer-facing implementation guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.
The exact FDA package describes on-premises and cloud deployment modes for the MVision AI Segmentation release; verify current hosting, contracts, security, availability, and site configuration locally.
exact submission · checked 2026-09-04
FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.
The exact FDA package describes DICOM TCP/IP for on-premises use and de-identified DICOM over HTTPS/TLS for cloud mode; verify the installed release and local controls.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Initial contours require professional visualization, review, modification, and approval; the labeled software is not intended for lesion or tumor detection or real-time adaptive planning.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.
Monitor K212915 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Initial contours require professional visualization, review, modification, and approval; the labeled software is not intended for lesion or tumor detection or real-time adaptive planning.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. radiotherapy planning or image-processing software limits remain submission-specific.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
Authorized purpose: AVIEW RT ACS is a medical image-management and processing system for radiation-treatment planning with deep-learning auto-segmentation evidence described in the exact FDA decision material; the submission compares automated organ segmentation with a predicate using Dice similarity coefficient and 95% Hausdorff distance on CT cases.
Modality
Radiotherapy Planning Imaging
Anatomy
Organs at risk across breast, head and neck, abdomen, and pelvis CT validation cases, including lung, heart, eyes, brain, mandible, kidneys, liver, femur, and bladder
Authorized purpose: DeepBT Detector-Plus provides initial gross-tumor-volume contours on T1-weighted contrast-enhanced and optional T2-weighted MR images for radiation-treatment planning in adults with the labeled brain tumors.
Modality
Radiotherapy Planning Imaging
Anatomy
Brain tumors, including metastases, meningiomas, and acoustic neuromas
Authorized purpose: Contour ProtégéAI+ automatically creates contours on CT and T2 MR DICOM images as an accessory to MIM software for quantitative analysis, adaptive therapy, transfer, and archive; users must review and edit contours, and the device is not intended to detect or contour lesions.
Modality
Radiotherapy Planning Imaging
Anatomy
CT anatomical regions; prostate, seminal vesicles, and urethra on T2 MR
Authorized purpose: DeepContour uses deep-learning CT processing to generate editable organ contours and RTSTRUCT objects for selected adult radiation-treatment planning workflows, with quantitative statistics, registration, and three-dimensional visualization; it does not contour tumors.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.